Table 1 Baseline characteristics
2015 | 2016 | 2017 | ||||
|---|---|---|---|---|---|---|
Patients | 7958 | 7804 | 7709 | |||
Deaths | 138 | 114 | 124 | |||
Patients, excl. Deaths | 7820 | 7690 | 7585 | |||
OAT | OAT + AMb | OAT | OAT + AMb | OAT | OAT + AMb | |
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
Dispensed ADHD medication | – | 274 (3.5) | – | 312 (4.1) | – | 349 (4.6) |
Age | ||||||
≤ 25 | 171 (2.2) | 5 (1.8) | 135 (1.8) | 7 (2.2) | 120 (1.6) | 9 (2.6) |
26–35 | 1551 (19.8) | 81 (29.6) | 1403 (18.2) | 90 (28.8) | 1333 (17.6) | 84 (24.1) |
36–45 | 2605 (33.3) | 107 (39.1) | 2508 (32.6) | 118 (37.8) | 2392 (31.5) | 134 (38.4) |
46–55 | 2544 (32.5) | 69 (25.2) | 2540 (33.0) | 79 (25.3) | 2548 (33.6) | 97 (27.8) |
≥ 56 | 949 (12.1) | 12 (4.4) | 1104 (14.4) | 18 (5.8) | 1192 (15.7) | 25 (7.2) |
Mean (SD) | 43.9 (9.7) | 41.0 (8.5) | 44.5 (9.8) | 40.8 (8.7) | 45.0 (9.9) | 41.8 (9.0) |
Gender | ||||||
Male | 5430 (69.4) | 193 (70.4) | 5354 (69.6) | 221 (70.8) | 5245 (69.1) | 254 (72.8) |
Female | 2390 (30.6) | 81 (29.6) | 2336 (30.4) | 91 (29.2) | 2340 (30.9) | 92 (26.4) |
OAT opioidsa | ||||||
Methadone (included levomethadone) | 3216 (41.1) | 72 (26.3) | 3066 (39.9) | 74 (23.7) | 2981 (39.3) | 92 (26.4) |
Buprenorphine (included combinations) | 4604 (58.9) | 202 (73.7) | 4624 (60.1) | 238 (76.3) | 4604 (60.7) | 257 (73.6) |